These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 19817870)

  • 21. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II).
    Jacobsen PK
    J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):55-68. PubMed ID: 16470484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin II antagonists--therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy.
    Ribeiro AB
    Curr Med Res Opin; 2006 Jan; 22(1):1-16. PubMed ID: 16393425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel Sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats.
    Izuhara Y; Sada T; Yanagisawa H; Koike H; Ohtomo S; Dan T; Ito S; Nangaku M; van Ypersele de Strihou C; Miyata T
    Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1767-73. PubMed ID: 18658044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients.
    Böger CA; Götz AK; Krüger B; Hösl M; Schmitz G; Riegger GA; Krämer BK
    Eur J Med Res; 2005 Apr; 10(4):161-8. PubMed ID: 15946912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical studies on the blockade of the renin-angiotensin-aldosterone-system.
    Hennig L
    Clin Nephrol; 2003 Jul; 60 Suppl 1():S53-8. PubMed ID: 12940534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Blockade of the renin-angiotensin system by a combination of ACE inhibitors and AT1 receptor antagonists].
    Azizi M
    Rev Prat; 2004 Jun; 54(11):1167-74. PubMed ID: 15496022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes.
    Cao Z; Cooper ME
    Acta Diabetol; 2012 Aug; 49(4):243-54. PubMed ID: 21947383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The significance of generic valsartan in the treatment of patients].
    Vértes A
    Lege Artis Med; 2011 Feb; 21(2):117-21. PubMed ID: 21710709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preventing diabetes in patients with hypertension: one more reason to block the renin-angiotensin system.
    Cooper ME; Tikellis C; Thomas MC
    J Hypertens Suppl; 2006 Mar; 24(1):S57-63. PubMed ID: 16601575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review.
    Sjølie AK; Dodson P; Hobbs FR
    Int J Clin Pract; 2011 Feb; 65(2):148-53. PubMed ID: 21235695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of local and systemic angiotensin in diabetic renal disease.
    Anderson S
    Kidney Int Suppl; 1997 Dec; 63():S107-10. PubMed ID: 9407435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How to explain the differences between renin angiotensin system modulators.
    Levy BI
    Am J Hypertens; 2005 Sep; 18(9 Pt 2):134S-141S. PubMed ID: 16125050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum?
    Schmieder RE
    J Hypertens Suppl; 2006 Apr; 24(2):S31-5. PubMed ID: 16601559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetes and retinal vascular disorders: role of the renin-angiotensin system.
    Wilkinson-Berka JL
    Expert Rev Mol Med; 2004 Jul; 6(15):1-18. PubMed ID: 15387897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-term treatment of stroke-prone spontaneously hypertensive rats with an AT1 receptor blocker protects against hypertensive end-organ damage by prolonged inhibition of the renin-angiotensin system.
    Hamaguchi R; Takemori K; Inoue T; Masuno K; Ito H
    Clin Exp Pharmacol Physiol; 2008 Oct; 35(10):1151-5. PubMed ID: 18518883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Renin-Angiotensin system and vascular disease in diabetes.
    Deinum J; Chaturvedi N
    Semin Vasc Med; 2002 May; 2(2):149-56. PubMed ID: 16222606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of renin angiotensin system decreases renal protein oxidative damage in diabetic rats.
    Portero-Otín M; Pamplona R; Boada J; Jové M; Gonzalo H; Buleon M; Linz W; Schäfer S; Tack I; Girolami JP
    Biochem Biophys Res Commun; 2008 Apr; 368(3):528-35. PubMed ID: 18243127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of protective effects induced by blockade of the renin-angiotensin system: novel role of the pancreatic islet angiotensin-generating system in Type 2 diabetes.
    Leung PS
    Diabet Med; 2007 Feb; 24(2):110-6. PubMed ID: 17257271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers.
    Nickenig G; Ostergren J; Struijker-Boudier H
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S1-7. PubMed ID: 16969748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.